Healthcare [ 10/13 ] | Biotechnology [ 90/160 ]
NYSE MKT | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 2, 23 | -0.49 Decreased by -28.95% | -0.53 Increased by +7.55% |
| Aug 14, 23 | -0.58 Decreased by -75.76% | -0.48 Decreased by -20.83% |
| May 15, 23 | -0.43 Decreased by -86.96% | -0.42 Decreased by -2.38% |
| Mar 31, 23 | -0.43 Decreased by -19.44% | -0.35 Decreased by -22.86% |
| Nov 16, 22 | -0.38 Decreased by -26.67% | -0.3 Decreased by -26.67% |
| Aug 12, 22 | -0.33 Decreased by -32% | 0.51 Decreased by -164.71% |
| May 13, 22 | -0.23 Increased by +20.69% | -0.31 Increased by +25.81% |
| Mar 25, 22 | -0.36 Increased by +2.7% | -0.3 Decreased by -20% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by -100% | -13.28 M Decreased by -45.11% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by -100% | -15.18 M Decreased by -97.57% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by -100% | -10.49 M Decreased by -105.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 114 K Increased by +395.65% | -10 M Decreased by -24.88% | Decreased by -8.77 K% Increased by +74.8% |
| Sep 30, 22 | 45 K Decreased by -80.69% | -9.15 M Decreased by -42.44% | Decreased by -20.33 K% Decreased by -637.53% |
| Jun 30, 22 | 45 K Decreased by -83.08% | -7.68 M Decreased by -53.04% | Decreased by -17.08 K% Decreased by -804.62% |
| Mar 31, 22 | 940 K Increased by +51.13% | -5.09 M Increased by +4.25% | Decreased by -541.91% Increased by +36.64% |
| Dec 31, 21 | 23 K Increased by +N/A% | -8.01 M Decreased by -25.55% | Decreased by -34.83 K% Decreased by N/A% |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iomab-ACT for GeneTx and cell therapy conditioning, Actimab-A (CD33) and CLAG-M, Actimab-A (CD33) and Venetoclax, and Actimab-A (CD33) and Venetoclax with HMA. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 -SIRPa immunotherapy targeted radiotherapy; AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors; and Immedica pharma for licensed the rights to commercialize Iomab-B. The company is based in New York, New York.